查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1481780

全球腫瘤學伴隨診斷測試市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Companion Diagnostic Tests in Oncology Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 281 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2032 年，全球腫瘤市場伴隨診斷測試的市場規模將從 2023 年的 58.9 億美元達到近 139.9 億美元，2024-2032 年研究期間複合年成長率為 10.09%。

腫瘤學中的伴隨診斷測試旨在識別與患者的癌症診斷或預後相關的特定生物標記或分子標靶。這些測試與標靶癌症療法一起使用，以個性化治療決策、預測治療反應並監測疾病進展。這些測試分析生物樣本，如組織活體組織切片、血液樣本或循環腫瘤 DNA，以檢測基因突變、基因擴增、蛋白質表現量或其他指示癌症亞型、分期或治療反應的分子變化。透過提供有關患者腫瘤生物學的可行資訊，伴隨診斷測試使腫瘤學家能夠在精準腫瘤學實踐中製定治療策略、最佳化治療選擇並改善患者的治療效果。

市場動態

全球癌症的流行，加上分子生物學和基因組學的進步，正在推動用於個人化癌症治療的伴隨診斷測試的開發和採用。此外，對精準醫療和基於價值的醫療保健的日益重視推動了對輔助診斷測試的需求，這些測試有助於最佳化治療結果、最大限度地減少不良反應並降低醫療成本。此外，監管機構簡化藥物核准流程和鼓勵標靶治療開發的措施正在推動對伴隨診斷測試開發和商業化的投資。此外，製藥公司、診斷實驗室和研究機構之間的合作和夥伴關係推動創新並加速針對新興生物標記和治療標靶的伴隨診斷測試的開發。此外，液體活體組織切片和新一代定序 (NGS) 技術的日益普及正在擴大伴隨診斷測試的範圍和能力，從而能夠對腫瘤進行非侵入性和全面的分析，以實現精準腫瘤學應用。然而，不斷變化的監管環境和報銷挑戰可能會對未來幾年腫瘤學市場成長的伴隨診斷測試提出挑戰。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球腫瘤學伴隨診斷測試市場的每個細分市場進行了包容性評估。腫瘤學產業伴隨診斷測試的成長和趨勢為這項研究提供了整體方法。

市場區隔

腫瘤學市場報告中的伴隨診斷測試的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依檢測技術

  • 蛋白質檢測（免疫組織化學）
  • DNA 檢測（聚合酶鍊式反應 (Pcr)、新一代定序 (NGs)、原位雜合技術）
  • 其他

透過生物標記

  • 表皮生長因子受體
  • 克拉斯
  • HER2
  • 布拉夫V600E
  • 其他

按癌症類型

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 肝癌
  • 黑色素瘤
  • 其他

按最終用戶

  • 醫院
  • 專科診所
  • 診斷實驗室
  • 其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲腫瘤學伴隨診斷測試市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。腫瘤伴隨診斷測試市場的主要參與者包括 Abbott、F. Hoffmann-LA Roche AG、Genomic Health, Inc.、Qiagen、Agilent Technologies, Inc.、Agendia NV、bioMerieux SA、Illumina, Inc.、Siemens Healthineers、賽默飛世爾科技公司、BioGenex。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：腫瘤學中的伴隨診斷測試 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 透過檢測技術進行市場吸引力分析
    • 生物標記的市場吸引力分析
    • 按癌症類型分類的市場吸引力分析
    • 最終用戶的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：腫瘤學市場分析中的全球伴隨診斷測試：按檢測技術

  • 依檢測技術概述
  • 歷史和預測數據
  • 檢測技術分析
  • 蛋白質檢測（免疫組織化學）
  • DNA 檢測（聚合酶鍊式反應 (PCR)、新一代定序 (NGS)、原位雜合技術）
  • 其他

第 6 章：腫瘤學市場分析中的全球伴隨診斷測試：按生物標記

  • 生物標記概述
  • 歷史和預測數據
  • 生物標記分析
  • 表皮生長因子受體
  • 克拉斯
  • HER2
  • 布拉夫V600E
  • 其他

第 7 章：腫瘤學市場分析中的全球伴隨診斷測試：按癌症類型

  • 按癌症類型概述
  • 歷史和預測數據
  • 按癌症類型分析
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 肝癌
  • 黑色素瘤
  • 其他

第 8 章：腫瘤學市場分析中的全球伴隨診斷測試：按最終用戶

  • 最終用戶概述
  • 歷史和預測數據
  • 最終用戶分析
  • 醫院
  • 專科診所
  • 診斷實驗室
  • 其他

第 9 章：腫瘤學市場分析中的全球伴隨診斷測試：按地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：腫瘤公司伴隨診斷測試的競爭格局

  • 腫瘤學市場競爭中的伴隨診斷測試
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Abbott
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • F. Hoffmann-LA Roche AG
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Genomic Health Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • QIAGEN
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Agilent Technologies Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Agendia NV
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • BioMeRieux SA
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Illumina Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Siemens Healthineers
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Thermo Fisher Scientific Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • BioGenex.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR112114403

The global demand for Companion Diagnostic Tests in Oncology Market is presumed to reach the market size of nearly USD 13.99 Billion by 2032 from USD 5.89 Billion in 2023 with a CAGR of 10.09% under the study period 2024 - 2032.

Companion diagnostic tests in oncology are designed to identify specific biomarkers or molecular targets associated with a patient's cancer diagnosis or prognosis. These tests are used with targeted cancer therapies to personalize treatment decisions, predict treatment response, and monitor disease progression. These tests analyze biological samples such as tissue biopsies, blood samples, or circulating tumor DNA to detect genetic mutations, gene amplifications, protein expression levels, or other molecular alterations indicative of cancer subtype, stage, or treatment response. By providing actionable information about a patient's tumor biology, companion diagnostic tests enable oncologists to tailor treatment strategies, optimize therapy selection, and improve patient outcomes in precision oncology practice.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide, coupled with advancements in molecular biology and genomics, is driving the development and adoption of companion diagnostic tests for personalized cancer treatment. Additionally, the escalating emphasis on precision medicine and value-based healthcare drives demand for companion diagnostic tests that help optimize treatment outcomes, minimize adverse effects, and reduce healthcare costs. Moreover, regulatory agencies' initiatives to streamline drug approval processes and encourage the development of targeted therapies are driving investment in companion diagnostic test development and commercialization. Furthermore, collaborations and partnerships between pharmaceutical companies, diagnostic laboratories, and research institutions drive innovation and accelerate the development of companion diagnostic tests for emerging biomarkers and therapeutic targets. Additionally, the growing adoption of liquid biopsy and next-generation sequencing (NGS) technologies is expanding the scope and capabilities of companion diagnostic tests, enabling non-invasive and comprehensive profiling of tumors for precision oncology applications. However, the evolving regulatory landscape and reimbursement challenges may challenge the companion diagnostic tests in oncology market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of companion diagnostic tests in oncology. The growth and trends of companion diagnostic tests in oncology industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the companion diagnostic tests in oncology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Detection Technique

  • Protein Detection (Immunohistochemistry)
  • DNA Detection (Polymerase Chain Reaction (Pcr), Next-Generation Sequencing (Ngs), In Situ Hybridization)
  • Others

By Biomarker

  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Melanoma
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Labs
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Companion Diagnostic Tests in Oncology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Companion Diagnostic Tests in Oncology market include Abbott, F. Hoffmann-LA Roche AG, Genomic Health, Inc., Qiagen, Agilent Technologies, Inc., Agendia N.V., bioMerieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., BioGenex. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Detection Technique
    • 3.7.2 Market Attractiveness Analysis By Biomarker
    • 3.7.3 Market Attractiveness Analysis By Cancer Type
    • 3.7.4 Market Attractiveness Analysis By End-user
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY DETECTION TECHNIQUE

  • 5.1. Overview By Detection Technique
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Detection Technique
  • 5.4. Protein Detection (Immunohistochemistry) Historic and Forecast Sales By Regions
  • 5.5. DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Historic and Forecast Sales By Regions
  • 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY BIOMARKER

  • 6.1. Overview By Biomarker
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Biomarker
  • 6.4. EGFR Historic and Forecast Sales By Regions
  • 6.5. KRAS Historic and Forecast Sales By Regions
  • 6.6. HER2 Historic and Forecast Sales By Regions
  • 6.7. BRAF V600E Historic and Forecast Sales By Regions
  • 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY CANCER TYPE

  • 7.1. Overview By Cancer Type
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Cancer Type
  • 7.4. Breast Cancer Historic and Forecast Sales By Regions
  • 7.5. Lung Cancer Historic and Forecast Sales By Regions
  • 7.6. Colorectal Cancer Historic and Forecast Sales By Regions
  • 7.7. Liver Cancer Historic and Forecast Sales By Regions
  • 7.8. Melanoma Historic and Forecast Sales By Regions
  • 7.9. Others Historic and Forecast Sales By Regions

8. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY END-USER

  • 8.1. Overview By End-user
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By End-user
  • 8.4. Hospitals Historic and Forecast Sales By Regions
  • 8.5. Specialty Clinics Historic and Forecast Sales By Regions
  • 8.6. Diagnostic Labs Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE COMPANION DIAGNOSTIC TESTS IN ONCOLOGY COMPANIES

  • 10.1. Companion Diagnostic Tests in Oncology Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF COMPANION DIAGNOSTIC TESTS IN ONCOLOGY INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Abbott
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. F. Hoffmann-LA Roche AG
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Genomic Health Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. QIAGEN
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Agilent Technologies Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Agendia N.V.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. BioMeRieux SA
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Illumina Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Siemens Healthineers
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Thermo Fisher Scientific Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. BioGenex.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Detection Technique (USD MN)
  • Protein Detection (Immunohistochemistry) Market Sales By Geography (USD MN)
  • DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Biomarker (USD MN)
  • EGFR Market Sales By Geography (USD MN)
  • KRAS Market Sales By Geography (USD MN)
  • HER2 Market Sales By Geography (USD MN)
  • BRAF V600E Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Cancer Type (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Lung Cancer Market Sales By Geography (USD MN)
  • Colorectal Cancer Market Sales By Geography (USD MN)
  • Liver Cancer Market Sales By Geography (USD MN)
  • Melanoma Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Diagnostic Labs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Companion Diagnostic Tests in Oncology Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Companion Diagnostic Tests in Oncology Report
  • Market Research Process
  • Market Research Methodology
  • Global Companion Diagnostic Tests in Oncology Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Detection Technique
  • Market Attractiveness Analysis By Biomarker
  • Market Attractiveness Analysis By Cancer Type
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Detection Technique (USD MN)
  • Protein Detection (Immunohistochemistry) Market Sales By Geography (USD MN)
  • DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Biomarker (USD MN)
  • EGFR Market Sales By Geography (USD MN)
  • KRAS Market Sales By Geography (USD MN)
  • HER2 Market Sales By Geography (USD MN)
  • BRAF V600E Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Cancer Type (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Lung Cancer Market Sales By Geography (USD MN)
  • Colorectal Cancer Market Sales By Geography (USD MN)
  • Liver Cancer Market Sales By Geography (USD MN)
  • Melanoma Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Diagnostic Labs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.